TMCnet News
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Obalon Therapeutics, Inc. - OBLNRosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Obalon Therapeutics, Inc. (NASDAQ:OBLN) resulting from allegations that Obalon may have issued materially misleading business information to the investing public. On January 23, 2018, Obalon announced it would cancel its previously announced public offering of Obalon common stock after its independent auditor, KPMG LLP, received a complaint from a "purported whistleblower" alleging "improper revenue recognition during the Company's fourth fiscal quarter of 2017." On this news, shares of Obalon fell $1.73 per share or over 33% from its previous closing price to close at $3.46 per share on January 23, 2018. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Obalon investors. If you purchased shares of Obalon, please visit the firm's website at http://www.rosenlegal.com/cases-1275.html or more information. You may also contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Follow us for updates on LinkedIn (News - Alert): https://www.linkedin.com/company/the-rosen-law-firm or on Twitter (News - Alert): https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123006551/en/ |
